Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1996 Mar;51(3):238–247. doi: 10.1136/thx.51.3.238

British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

G J Gibson 1, R J Prescott 1, M F Muers 1, W G Middleton 1, D N Mitchell 1, C K Connolly 1, B D Harrison 1
PMCID: PMC1090632  PMID: 8779124

Abstract

BACKGROUND: Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven. METHODS: Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function. Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. RESULTS: One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was 9% of the predicted value. Side effects of treatment were frequent but usually mild, necessitating withdrawal in only two individuals. CONCLUSIONS: After excluding those individuals who required steroids for control of symptoms, approximately half of the remaining patients with sarcoidosis and pulmonary shadowing showed spontaneous radiographic improvement during six months of observation. In those in whom the radiograph failed to improve, prolonged steroid treatment with the aim of optimising radiographic appearances resulted in a significantly better long term functional outcome.

Full text

PDF
238

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colp C. Sarcoidosis: course and treatment. Med Clin North Am. 1977 Nov;61(6):1267–1278. doi: 10.1016/s0025-7125(16)31261-5. [DOI] [PubMed] [Google Scholar]
  2. DeRemee R. A. The present status of treatment of pulmonary sarcoidosis: a house divided. Chest. 1977 Mar;71(3):388–393. doi: 10.1378/chest.71.3.388. [DOI] [PubMed] [Google Scholar]
  3. Douglas J. G., Middleton W. G., Gaddie J., Petrie G. R., Choo-Kang Y. F., Prescott R. J., Crompton G. K. Sarcoidosis: a disorder commoner in non-smokers? Thorax. 1986 Oct;41(10):787–791. doi: 10.1136/thx.41.10.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eule H., Weinecke A., Roth I., Wuthe H. The possible influence of corticosteroid therapy on the natural course of pulmonary sarcoidosis. Late results of a continuing clinical study. Ann N Y Acad Sci. 1986;465:695–701. doi: 10.1111/j.1749-6632.1986.tb18548.x. [DOI] [PubMed] [Google Scholar]
  5. Harkleroad L. E., Young R. L., Savage P. J., Jenkins D. W., Lordon R. E. Pulmonary sarcoidosis. Long-term follow-up of the effects of steroid therapy. Chest. 1982 Jul;82(1):84–87. doi: 10.1378/chest.82.1.84. [DOI] [PubMed] [Google Scholar]
  6. Harrison B. D., Shaylor J. M., Stokes T. C., Wilkes A. R. Airflow limitation in sarcoidosis--a study of pulmonary function in 107 patients with newly diagnosed disease. Respir Med. 1991 Jan;85(1):59–64. doi: 10.1016/s0954-6111(06)80211-8. [DOI] [PubMed] [Google Scholar]
  7. Israel H. L., Fouts D. W., Beggs R. A. A controlled trial of prednisone treatment of sarcoidosis. Am Rev Respir Dis. 1973 Apr;107(4):609–614. doi: 10.1164/arrd.1973.107.4.609. [DOI] [PubMed] [Google Scholar]
  8. James D. G., Carstairs L. S., Trowell J., Sharma O. P. Treatment of sarcoidosis. Report of a controlled therapeutic trial. Lancet. 1967 Sep 9;2(7515):526–528. doi: 10.1016/s0140-6736(67)90493-x. [DOI] [PubMed] [Google Scholar]
  9. Johns C. J., Zachary J. B., Ball W. C., Jr A ten-year study of corticosteroid treatment of pulmonary sarcoidosis. Johns Hopkins Med J. 1974 May;134(5):271–283. [PubMed] [Google Scholar]
  10. SCADDING J. G. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J. 1961 Nov 4;2(5261):1165–1172. doi: 10.1136/bmj.2.5261.1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Selroos O., Sellergren T. L. Corticosteroid therapy of pulmonary sarcoidosis. A prospective evaluation of alternate day and daily dosage in stage II disease. Scand J Respir Dis. 1979 Aug;60(4):215–221. [PubMed] [Google Scholar]
  12. Young R. L., Harkleroad L. E., Lordon R. E., Weg J. G. Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy. Ann Intern Med. 1970 Aug;73(2):207–212. doi: 10.7326/0003-4819-73-2-207. [DOI] [PubMed] [Google Scholar]
  13. Zaki M. H., Lyons H. A., Leilop L., Huang C. T. Corticosteroid therapy in sarcoidosis. A five-year, controlled follow-up study. N Y State J Med. 1987 Sep;87(9):496–499. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES